MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-026-16521-1

Медицинская библиотека · BMC cancer · 2026

Validation and prognostic utility of the mSMART 4.0 risk stratification system in Chinese patients with multiple myeloma.

Yin Jian, Liu Rui, Zhang Yanping, Liu Zeshi, Gong Yangyang, He Aili

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

The 2024 Mayo Clinic mSMART 4.0 risk stratification system features significant revisions, yet its utility in Chinese multiple myeloma (MM) patients remains unvalidated. This study evaluates its prognostic performance in a Chinese cohort.

METHODS

We retrospectively collected clinical data from newly diagnosed MM (NDMM) patients and followed them up. Clinical characteristics, therapeutic responses, and survival were compared between high-risk and standard-risk groups defined by mSMART 4.0. Harrell's concordance index (C-index) analysis was used to compare the predictive efficacy of mSMART 4.0 versus version 3.0.

RESULTS

Among 202 patients, 69 (34.2%) were high-risk according to mSMART 4.0. The mSMART 4.0 high-risk group demonstrated significantly lower deep response rates, alongside shorter median PFS (P < 0.001) and OS (P < 0.001). The proportion of the high-risk group was lower under mSMART 4.0 (34.2%) compared to mSMART 3.0 (51.9%). C-index revealed that mSMART 4.0 possessed superior prognostic predictive validity (C-index = 0.738, 95% CI: 0.677-0.792) relative to mSMART 3.0 (C-index = 0.572, 95% CI: 0.490-0.649). The increase in the C-index was statistically significant (ΔC-index = 0.167, 95% CI: 0.065-0.269, P = 0.003). Multivariate analysis identified mSMART 4.0 high-risk status as an independent adverse prognostic factor for both PFS (HR = 2.027; 95% CI: 1.364-3.012) and OS (HR = 5.352; 95% CI: 2.794-10.250). Additionally, elevated lactate dehydrogenase (LDH) was an independent predictor of poor PFS (HR = 1.002; 95% CI: 1.001-1.004).

CONCLUSION

In this Chinese cohort, mSMART 4.0 effectively stratifies multiple myeloma patients and serves as an independent predictor of inferior prognosis, demonstrating superior prognostic value over version 3.0.

Для цитирования: Yin Jian, Liu Rui, Zhang Yanping, Liu Zeshi, Gong Yangyang, He Aili. Validation and prognostic utility of the mSMART 4.0 risk stratification system in Chinese patients with multiple myeloma.. BMC cancer. 2026. DOI: 10.1186/s12885-026-16521-1.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.